A RECENT letter by the Malaysian Health Coalition (MHC) and the Drugs for Neglected Diseases Initiative (DNDi) has highlighted once again how people living in low- and middle-income countries like Malaysia are frequently denied access to affordable, life-saving medicines.
By excluding Malaysia from its voluntary licensing agreements, the biopharmaceutical company Gilead Sciences has denied Malaysians access to affordable generic versions of remdesivir, a potential treatment for Covid-19, thus forcing us to pay whatever price it charges.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
